Shares of Cassava Sciences, Inc. (SAVA) are surging more than 55% Tuesday morning after the company reported positive data from the study of its lead drug candidate, simufilam for the treatment of Alzheimer's disease.
Results from an interim analysis of open-label study of simufilam showed improvement in cognition and behavior in patients with Alzheimer's disease, following six months of treatment, with no safety issues, Cassava said.
The company also said that there were no drug-related serious adverse events. Adverse events were mild and transient.
Cassava Sciences believes today's data and prior clinical results support advancing simufilam into a Phase III study, which the company plans to begin in the second half 2021.
SAVA toched a new high of $45.62 this morning and currently trading down at $35.83.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.